Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
We compared various amphotericin B formulations (no treatment or 0.8 mg of Fungizone [conventional deoxycholate amphotericin B] per kg of body weight, or 0.8, 4, or 8 mg of Amphocil, AmBisome, or Abelcet per kg of body weight) for treatment of systemic murine aspergillosis. In two studies, all formulations prolonged survival, with the results for AmBisome nearly equivalent to those for Fungizone; Amphocil and Abelcet were less effective or equivalent depending on the severity of infection. No survivors were cured in both kidneys and brain, but each formulation showed efficacy, especially in the kidneys. Although higher doses could be given, no lipid-based formulation showed consistent superiority over Fungizone or over each other.
California Institute for Medical Research and Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, USA. clemons@cimr.org
Karl V
KV
Clemons
David A
DA
Stevens
D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001921:Brain / Q000382:microbiology; D002626:Chemistry, Pharmaceutical; D015169:Colony Count, Microbial; D004337:Drug Carriers; D005079:Excipients; D005260:Female; D007668:Kidney / Q000382:microbiology; D008081:Liposomes; D051379:Mice; D013534:Survival; D016019:Survival Analysis
D000935:Antifungal Agents; D004337:Drug Carriers; D005079:Excipients; D008081:Liposomes; D000666:Amphotericin B